Baseline Lymphopenia Predicts Survival in ICI-Naïve Solid Tumor Patients Receiving Immune Checkpoint Inhibitors: A Propensity-Matched Real-World Pan-Cancer Analysis
Ahmed Ismail, Nina Balanchivadze, George R. Simon, Yanis Boumber · 2026
Read Baseline Lymphopenia Predicts Survival in ICI-Naïve Solid Tumor Patients Receiving Immune Checkpoint Inhibitors: A Propensity-Matched Real-World Pan-Cancer Analysis by Ahmed Ismail, Nina Balanchivadze, George R. Simon, Yanis Boumber (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13297561.txt.
Description
Ahmed Ismail and colleagues ask whether a low lymphocyte count before immunotherapy marks cancer patients headed for worse outcomes, in a 2026 study of health records. Lymphocytes are the white cells that immune checkpoint drugs unleash against tumours. The team used a large United States record network and matched patients with low counts to similar patients with normal counts.
Patients starting treatment with low counts lived shorter lives across tumour types. They also needed more hospital care soon after starting and may have suffered more serious infections. Immune side effects, though, showed no clear rise. A cheap, routine blood test could thus flag patients who need closer watching and support during treatment.
Catalog record
| CREATOR | Ahmed Ismail, Nina Balanchivadze, George R. Simon, Yanis Boumber |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |